-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
scFvs have considerable therapeutic potential against antigens (Ags) involved in disease processes (
1,2)
, either as proteins synthesized ex vivo for passive administration, or introduced by gene therapy for in vivo expression. Their small size confers many pharmacological advantages, compared to whole antibodies (Abs). However, they lack intrinsic biological activity because they lack the Fc (effector) portion of native (whole) Abs. Biological activity can be imparted to scFvs by generating bifunctional molecules, in which the scFv that specifically recognizes an Ag on the target cells is genetically fused to an effector molecule. Examples include cytokines (
3,4
) or prodrug-converting enzymes (
1,5,6
). Alternatively, the effector molecule can be a second scFv that retargets the molecules toward a cell population, e.g., for activation of cytotoxic T cells (
7
) or for gene therapy, e.g., targeting recombinant adenoviruses carrying therapeutic genes (
8
).